Advances in Therapy

, Volume 24, Issue 2, pp 310–318

Intravenous conivaptan: Effects on the QTc interval and other electrocardiographic parameters in healthy volunteers

  • Kenneth C. Lasseter
  • Stacy C. Dilzer
  • Neila Smith

DOI: 10.1007/BF02849899

Cite this article as:
Lasseter, K.C., Dilzer, S.C. & Smith, N. Adv Therapy (2007) 24: 310. doi:10.1007/BF02849899


Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure. After a placebo run-in period, participants in this randomized, single-blind, placebo- and positive-controlled, parallel-group study received an intravenous 20-mg loading dose of conivaptan (day 1), followed by a 40-mg/d continuous infusion (days 1–4); a 20-mg loading dose of conivaptan (day 1), followed by an 80-mg/d continuous infusion (days 1–4); or moxifloxacin 400 mg (positive control) or placebo from day 1 to day 4. The primary ECG endpoint was QTc interval duration, which was determined by the individually corrected QT interval for each subset; secondary endpoints included QT intervals corrected with Bazett’s formula and Fridericia’s formula. No clinically notable changes in ECG parameters were associated with conivaptan, suggesting that conivaptan did not affect cardiac repolarization or cardiac conduction.


conivaptan QT interval electrocardiogram 

Copyright information

© Springer Science and Business Media and LLC 2007

Authors and Affiliations

  • Kenneth C. Lasseter
    • 1
  • Stacy C. Dilzer
    • 1
  • Neila Smith
    • 2
  1. 1.SFBC InternationalMiami
  2. 2.Astellas Pharma US, IncDeerfield
  3. 3.Hialeah

Personalised recommendations